ArticleBlood research2021
Real-life ruxolitinib experience in intermediate-risk myelofibrosis.
Fatma Arikan et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
4 papers cite it
this papercites it
ArticleBlood research2021
Fatma Arikan et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.